Minghui Pharmaceutical Announces Promising Initial Results from Phase I Clinical Trial of MHB039A, a Novel PD-1 x VEGF Bispecific Antibody, in Patients with Relapsed/Refractory Solid Tumors
HTX Ventures: Fueling Exchanges' Transformation into Hubs for DeFi-related Services through Education and Diversification, Empowering investors to Manage Risks and Liquidity in a Volatile Market
SINGAPORE, Nov. 6, 2024 /PRNewswire/ — HTX Ventures, the global investment division…